Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation

Chronic Hepatitis c Clinical Trial

Official title:

An Open-label, Cohort Study of Grazoprevir/Elbasvir Combination Therapy for Patients With Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03723824
• Other study ID #: SF18281A
• Status: Terminated
• Phase: Phase 4
• Start date: February 14, 2019
• Est. completion date: March 13, 2021

Study information

• Verified date: March 2021
• Source: Taichung Veterans General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Grazoprevir/elbasvir combination therapy is highly effective in the treatment of genotype 1b chronic hepatitis C, and the drug-drug interaction with central immunosuppressant, such as tacrolimus, should be manageable. The aim of this study is to assess the efficacy and tolerability of grazoprevir/elbasvir combination therapy in treating genotype 1b chronic hepatitis C after liver or kidney transplantation.

Description:

Grazoprevir/elbasvir combination therapy (grazoprevir 100 mg/ elbasvir 50 mg, Zepatier®, MSD) has been recommended as the 1st-line treatment for genotype 1b chronic hepatitis C by the updated international guidelines, and the rates of sustained virologic response (SVR) can be higher than 95% in either treatment-naïve or peginterferon-experienced patients with genotype 1b chronic hepatitis C. Moreover, even among patients with liver cirrhosis, the efficacy of grazoprevir/elbasvir combination therapy remains very high. In addition, drug-related adverse effects (AEs) were quite low in previous studies, and less than 1% of cirrhotic patients discontinued this therapy during treatment period (4). Grazoprevir/elbasvir combination therapy is an effective and safe treatment for chronic hepatitis C. Chronic hepatitis C is one of the most common indications for liver transplantation. Patients underwent liver or kidney transplantation always suffer from recurrent chronic hepatitis C. Recurrent chronic hepatitis C can result in liver cirrhosis, liver decompensation, and death. Chronic hepatitis C is also associated with a higher incidence of chronic rejection, graft failure and mortality after kidney transplantation. Treating hepatitis C virus (HCV) infection after liver or kidney transplantation was a big challenge before the development of new direct-acting antiviral (DAA). Not only a low SVR rate but also a high rate of severe adverse effects results in the hesitation of peginterferon-ribavirin combination therapy. Although some new DAAs can be used in organ transplantation, the cost remains quite high. More new DAA choices for patients underwent organ transplantation are needed. The clinical data of grazoprevir/elbasvir combination therapy on the treatment for patients with chronic hepatitis C after liver or kidney transplantation remain lacking. With high virologic response rates and low adverse effects in the management for chronic hepatitis C, grazoprevir/elbasvir combination therapy could be a good option for patients underwent liver or kidney transplantation. No drug-drug interaction (DDI) was noted between grazoprevir/elbasvir combination therapy and steroid, and the DDI with the most commonly-used immunosuppressant, tacrolimus, was also not significant, The drug levels of immunosuppressants can be carefully monitored and adjusted during treatment period. The aim of this study is to assess the efficacy and tolerability of grazoprevir/elbasvir combination therapy in treating genotype 1b chronic hepatitis C after liver or kidney transplantation.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 14
• Est. completion date: March 13, 2021
• Est. primary completion date: November 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. At least 20 years of age

2. Chronically infected with genotypes 1b HCV

3. Underwent liver and/ or kidney transplantation

4. Without clinical or pathologic evidence of moderate or severe rejection

Exclusion Criteria:

1. HCV genotype other than 1b

2. Liver decompensation (Child-Pugh score > 6)

3. Co-infected with human immunodeficiency virus: Positive HIV1/2 or hepatitis B virus :

Positive HBsAg and detected HBV DNA

4. Prior exposure to an NS5A inhibitor

5. Any active malignancies

6. Hemoglobin level less than 10 g/dl

7. Platelet level of 75,000/mm3 or less

8. Alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase level 10 times or more the upper limit of normal

9. Total bilirubin level greater than 3 times or more the upper limit of normal

10. Albumin less than 3 g/dL

11. Using medication that is not considered safe to co-administer with , such as cyclosporine

12. Pregnant or breast-feeding women

13. Known allergy to grazoprevir or elbasvir (Unregistered liver or kidney transplant in other countries is illegal in Taiwan)

Related Conditions & MeSH terms

• Chronic Hepatitis c
• Communicable Diseases
• Hepatitis
• Hepatitis A
• Hepatitis C
• Hepatitis C, Chronic
• Hepatitis, Chronic
• Infection
• Kidney Transplant Infection
• Liver Transplant Infection

Intervention

Drug:
• grazoprevir 100 mg/ elbasvir 50 mg, Zepatier®
grazoprevir 100 mg/ elbasvir 50 mg (Zepatier®, MSD) once daily for 12 weeks

Locations

Country	Name	City	State
Taiwan	China Medical University Hospital	Taichung
Taiwan	Taichung Veterans General Hospital	Taichung

Sponsors (2)

Lead Sponsor	Collaborator
Taichung Veterans General Hospital	Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

Taiwan, 

References & Publications (3)

Jacobson IM, Lawitz E, Kwo PY, Hézode C, Peng CY, Howe AYM, Hwang P, Wahl J, Robertson M, Barr E, Haber BA. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis. Gastroe — View Citation

Kwo P, Gane EJ, Peng CY, Pearlman B, Vierling JM, Serfaty L, Buti M, Shafran S, Stryszak P, Lin L, Gress J, Black S, Dutko FJ, Robertson M, Wahl J, Lupinacci L, Barr E, Haber B. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavi — View Citation

Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sustained virologic response (SVR)	The HCV viral load (IU/mL) in blood at post-treatment week 12 (SVR12)	At post-treatment week 12
Secondary	Adverse effects (AEs)	Any AEs during the treatment period	During the treatment period (the 1st, 2nd, 4th, 6th, 8th, 10th, 12th weeks)
Secondary	Used immunosuppressant blood levels	The immunosuppressant concentration (ng/mL) in blood during the treatment period	During the treatment period (the 1st, 2nd, 4th, 6th, 8th, 10th, 12th weeks)